[{"id":"01bdc6f6-0410-48c7-88ae-60f097419d24","acronym":"","url":"https://clinicaltrials.gov/study/NCT03585517","created_at":"2023-08-14T10:10:59.415Z","updated_at":"2024-07-02T16:35:57.376Z","phase":"Phase 1","brief_title":"Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)","source_id_and_acronym":"NCT03585517","lead_sponsor":"Beijing Immunochina Medical Science \u0026 Technology Co., Ltd.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • IM23"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 07/21/2018","start_date":" 07/21/2018","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2023-01-19"}]